Delving into the Latest Updates on JD012-CEL with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

JD012-CEL

Target-

Action-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Beijing Jingda Biotechnology Co., Ltd.

Active Organization

Guangzhou Xiling Biotechnology Co., Ltd.

Beijing Jingda Biotechnology Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价JD012-CEL注射液治疗晚期实体肿瘤的安全性、耐受性。次要目的：评价JD012-CEL注射液治疗晚期实体肿瘤的抗肿瘤初步有效性。探索性目的：探索JD012-CEL注射液的药代动力学特征；探索JD012-CEL注射液输注后生物标志物变化。

[Translation]

Primary Objective: To evaluate the safety and tolerability of JD012-CEL injection in the treatment of advanced solid tumors. Secondary Objective: To evaluate the preliminary antitumor efficacy of JD012-CEL injection in the treatment of advanced solid tumors. Exploratory Objectives: To explore the pharmacokinetic characteristics of JD012-CEL injection; to explore changes in biomarkers after infusion of JD012-CEL injection.

Start Date-

Sponsor / Collaborator

Beijing Jingda Biotechnology Co., Ltd.

[+1]

100 Clinical Results associated with JD012-CEL

Login to view more data

100 Translational Medicine associated with JD012-CEL

Login to view more data

100 Patents (Medical) associated with JD012-CEL

Login to view more data

100 Deals associated with JD012-CEL

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	China	Guangzhou Xiling Biotechnology Co., Ltd.	06 Jan 2026
Advanced Malignant Solid Neoplasm	Phase 1	China	Beijing Jingda Biotechnology Co., Ltd.	06 Jan 2026